跳至主要内容
临床试验/ISRCTN17004671
ISRCTN17004671进行中(未招募)未知

Hemithyroidectomy or Total Thyroidectomy in 'low-risk' thyroid cancers

niversity College London0 个研究点目标入组 456 人开始时间: 2022年2月22日最近更新:
适应症

试验速览

阶段
未知
状态
进行中(未招募)
发起方
入组人数
456

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

性别
All

入选标准

  • Group 1 (Hemithyroidectomy already performed prior to diagnosis)
  • 1. Aged 16 or over
  • 2. Papillary thyroid cancer (PTC):
  • 2.1. pT1b-2 (=4cm) irrespective of molecular genetic markers
  • 2.2. R0 resection (clinically excised but microscopic R1 resected tumours at discretion of the local multidisciplinary team (MDT))
  • 2.3. cN0 or pN0, pNX & pN1a (=5 foci, no extranodal spread)
  • 2.4. Confined to thyroid or minimal extrathyroidal extension
  • 2.5. No higher risk histological variants on morphology (small foci allowed at the discretion of the local MDT)
  • 2.6. No angioinvasion
  • 2.7. Encapsulated follicular variant of PTC with capsular invasion only
  • 2.8. Micro-PTC (=1cm)
  • - multifocal
  • - unifocal with pN1a (=5 foci; no extranodal spread)
  • 3. Follicular thyroid cancer and oncocytic/Hurthle cell carcinoma:
  • 3.1. pT1b-2 (=4cm) irrespective of molecular genetic markers
  • - Minimally invasive, with capsular invasion +/- minimal (=4 foci) vascular invasion (the latter is now called encapsulated angioinvasive and is at the discretion of the MDT)
  • 3.2. Confined to thyroid or minimal extrathyroidal extension
  • Group 2 (Differentiated Thyroid Cancer on cytology/core biopsy, who has not had prior thyroid surgery yet)
  • 1. Aged 16 or over
  • 2. ‘low risk’ differentiated thyroid cancer confirmed by cytology or core biopsy.
  • 3. cT1b-2 irrespective of molecular genetic markers
  • 5. Contralateral lobe without suspicious nodule(s) (U2, or U3/U4 with Thy2 on FNAC)
  • Eligibility criteria for nested sub-study on Navio’s web-based app (software):
  • 1. Have a SMS enabled mobile phone or handheld tablet with web access
  • 2. Are able to use the web-based app to complete the trial questionnaires without assistance

排除标准

  • Group 1 (Hemithyroidectomy already performed prior to diagnosis):
  • 1. Tumour > 4cm
  • 2. Unifocal pT1a (< = 1cm) papillary thyroid cancer (PTC) and follicular thyroid cancer (FTC) (unless pN1a as listed in inclusion criteria)
  • 3. Non-invasive encapsulated follicular variant of PTC
  • 4. Anaplastic, poorly differentiated or medullary thyroid carcinoma
  • 5. R2 resection
  • 6. Gross extrathyroidal extension
  • 7. pT4 or macroscopic tumour invasion of loco-regional tissues or structures
  • 8. pN1a with > 5 foci or extranodal spread
  • 11. Aggressive PTC with any of the following features:
  • - Widely invasive
  • - Poorly differentiated
  • - Anaplastic
  • - predominance of Tall cell, Columnar cell, Hobnail, Diffuse sclerosing and other
  • higher risk variants
  • 12. FTC and oncocytic/Hürthle cell cancer with any of the following features:
  • - Minimally invasive with extensive vascular invasion (now called encapsulated angioinvasive) (> 4 foci)
  • - Widely invasive
  • - Poorly differentiated
  • - Anaplastic
  • Group 2 (Differentiated thyroid cancer on cytology or after core biopsy, who has not had prior thyroid surgery yet)

研究者

发起方
niversity College London

相似试验

HoT – A phase III randomised trial to compare the... | 临床试验